Skip to main content
SGIOY logo

Shionogi & Co., Ltd. (SGIOY) Stock Price & Analysis

Shionogi & Co., Ltd. (SGIOY) — price $9.81 (-0.61%), as of the Nov 18, 2026 trading session; market cap $16.7B.

Educational signal · not a buy or sell recommendation · How to read this

$9.81 −$0.06 (-0.61%) Market Cap $16.7B

Shionogi & Co., Ltd. · SGIOY · Healthcare · Drug Manufacturers - Specialty & Generic

Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan.

Price as of Nov 18, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ELAN · Elanco Animal Health Incorporated · 35 /100
  • RDY · Dr. Reddy's Laboratories Limited · 77 /100
  • VTRS · Viatris Inc. · 35 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$9.81
Change on the day-0.61%
52-week range$8.15–$12.00
Market capitalisation$16.7B—
Price / earnings (trailing)11.26
Shares traded on the day4.3K
Beta (volatility vs the S&P 500)0.03

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $7.95, high $12, latest $9.81. $12 $7.95 high $12 Oct 17, 2025 Nov 18, 2026 · $9.81 $7.97Oct 17, 2025$8.26Oct 31, 2025$8.79Nov 14, 2025$8.59Nov 28, 2025$8.49Dec 12, 2025$9.05Dec 26, 2025$9.25Jan 9, 2026$9.95Jan 23, 2026$11Feb 6, 2026$12Feb 20, 2026$11Mar 6, 2026$10Mar 20, 2026$11Apr 2, 2026$10Apr 17, 2026$9.86May 1, 2026$9.70May 15, 2026$9.34May 29, 2026$8.65Jun 12, 2026$8.52Jun 26, 2026$8.74Jul 10, 2026$8.68Jul 24, 2026$8.90Aug 7, 2026$9.18Aug 21, 2026$9.25Sep 4, 2026$9.32Sep 18, 2026$8.80Oct 2, 2026$9.18Oct 16, 2026$9.52Oct 30, 2026$9.87Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Shionogi & Co. (SGIOY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Strong
Revenue Growth Strong
Debt/Equity Neutral
ROE Moderate
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Shionogi & Co. (SGIOY), and what does it report?

Short answer

Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: 5-54 Ofukacho, Kita-KU, Grand Green Osaka, Park Tower 26F, Osaka, 530-0011. It employs 6,223 people and is led by Isao Teshirogi. The market values it at $16.7B.

3 · Financial strengths and risks

What are the financial strengths and risks for Shionogi & Co. (SGIOY)?

Short answer · as of

The distress and quality screens read Altman Z 3.24 · Piotroski F 5. Trailing ratios: ROE 14.4% · ROA 9.1% · current ratio 1.24 · earnings yield 8.7% · free-cash-flow yield 8.9%.

4 · What to check next?

What should you watch next at Shionogi & Co. (SGIOY)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $720.53B · EPS 136.00 · 5 analysts.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is Shionogi & Co. scored?

Research dated 2026-09-13.

Shionogi is classified with specialty and generic manufacturers, but its business is not a generic-volume proposition. It combines marketed infectious-disease medicines with diagnostic products, medical equipment and development programs spanning a wide range of therapeutic areas.

Compared with a narrower drugmaker, Shionogi carries a broader scientific agenda and a substantial recurring research burden. Consolidated gross profit, research spending and pipeline conversion therefore reveal more about its economics than the industry label alone.

SGIOY also offers an over-the-counter security tied to an Osaka-based Japanese operator. Its reported institutional footprint is sparse and the disclosed leading positions are limited, a distinction in the security’s ownership context rather than in the underlying medical portfolio.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Alibaba Health Information Technology Limited (ALBHF) Named competitor$0.37 Nov 18, 2026$5.98B— Model unavailable
Swedish Orphan Biovitrum AB (publ) (BIOVF) Named competitor$51.05 Nov 18, 2026$17.8B— Model unavailable
bioMérieux S.A. (BMXMF) Named competitor$102.14 Nov 18, 2026$12.0B— Model unavailable
CSPC Pharmaceutical Group Limited (CHJTF) Named competitor$1.12 Nov 18, 2026$12.8B— Model unavailable
Elanco Animal Health Incorporated (ELAN) Same industry, near in market value$26.70 Nov 18, 2026$13.4B— 5-pillar · not comparable
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.98 Nov 18, 2026$12.5B— 5-pillar · not comparable
Viatris Inc. (VTRS) Same industry, near in market value$20.28 Nov 18, 2026$23.3B— 5-pillar · not comparable
Zoetis Inc. (ZTS) Same industry, near in market value$85.57 Nov 18, 2026$34.8B— 5-pillar · not comparable
Amneal Pharmaceuticals, Inc. (AMRX) Same industry, near in market value$21.88 Nov 18, 2026$7.62B— 5-pillar · not comparable
Haleon plc (HLN) Same industry, near in market value$9.08 Nov 18, 2026$39.8B— 5-pillar · not comparable
Lantheus Holdings, Inc. (LNTH) Same industry, near in market value$102.00 Nov 18, 2026$6.67B— 5-pillar · not comparable
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.96 Nov 18, 2026$6.02B— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$720.53B
EPS estimate
$136.00

Measured against a quoted price of $9.81 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SGIOY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SGIOY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Shionogi & Co. (SGIOY) — Healthcare

These answers are editorial: 1 of these 8 answers is drawn from the SGIOY research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is SGIOY a good stock to buy?

Stock Expert AI does not rate SGIOY buy, sell or hold. Shionogi & Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SGIOY stock price today?

The last price recorded for Shionogi & Co., Ltd. (SGIOY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Shionogi & Co., Ltd. do?

Shionogi & Co., Ltd. is a research-driven pharmaceutical company focused on developing and commercializing innovative medicines. The company's core business involves the discovery, development, manufacture, and marketing of pharmaceutical products, diagnostic reagents, and medical devices.

What are the key factors to evaluate for SGIOY?

Evaluate SGIOY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This expansion could be achieved through partnerships or direct investment in overseas operations. Not financial advice.

How frequently does SGIOY data refresh on this page?

SGIOY's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SGIOY's recent stock price performance?

Shionogi & Co., Ltd. (SGIOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong pipeline of drugs in development. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SGIOY overvalued or undervalued right now?

The trailing P/E of Shionogi & Co., Ltd. (SGIOY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research SGIOY before investing?

Before investing in Shionogi & Co., Ltd. (SGIOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • 5. How is Shionogi & Co. scored?: Sector / industry (provider taxonomy); Business description; Ticker / exchange; Headquarters; Institutional ownership (13F); Largest 5 institutional holders
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.